Abstract #2011

Effect of Antiepileptic Treatment on Hippocampal Activity in Alzheimer’s Disease measured by ASL

Weiying Dai¹, Song Chen¹, Li Zhao², David Alsop², and Daniel Press³

¹Computer Science, State University of New York at Binghamton, Binghamton, NY, United States, ²Department of Radiology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States, ³Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, United States

Increased hippocampal perfusion in early AD has been reported, but the underlying mechanism is still not clear. We hypothesized that epileptiform activity occurs in the hippocampus with AD and causes increased perfusion. Here, we designed a placebo-controlled study using an antiepileptic drug, Levetiracetam to modulate epileptic activity of the hippocampus. Nine subjects with AD were scanned following drug or placebo. We observed decreased perfusion and increased perfusion fluctuation in entorhinal cortex with Levetiracetam. These findings support the potential epileptic activity effects of entorhinal cortex in AD. Due to neighboring locations of hippocampus and entorhinal cortex, further work will probe the effects of potential misregistration.

How to access this content:

For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.

After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.

After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.

Click here for more information on becoming a member.